Outlook Therapeutics® Announces Receipt of Type A Meeting Minutes and Reiterates Regulatory Path Forward for ONS-5010

<p>Resubmission of the ONS-5010 BLA on track for the end of calendar year 2024, pending final agreement on a clinical trial protocol with the FDA and successful completion of the required additional clinical trial Planned clinical trial expected to be a 3-month non-inferiority study with 60 day efficacy endpoint ISELIN, N.J., Nov. 27, 2023 (GLOBE […]</p>
<p>The post <a href="https://forextv.com/top-news/outlook-therapeutics-announces-receipt-of-type-a-meeting-minutes-and-reiterates-regulatory-path-forward-for-ons-5010/">Outlook Therapeutics® Announces Receipt of Type A Meeting Minutes and Reiterates Regulatory Path Forward for ONS-5010</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>